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Abstract
Acetylcholine (ACh), the first neurotransmitter to be identified, regulate the activities of central
and peripheral functions through interactions with muscarinic receptors. Changes in muscarinic
acetylcholine receptor (mAChR) have been implicated in the pathophysiology of many major
diseases of the central nervous system (CNS). Previous reports from our laboratory on
streptozotocin (STZ) induced diabetic rats showed down regulation of muscarinic M1 receptors in
the brainstem, hypothalamus, cerebral cortex and pancreatic islets. In this study, we have
investigated the changes of acetylcholine esterase (AChE) enzyme activity, total muscarinic and
muscarinic M1 receptor binding and gene expression in the corpus striatum of STZ – diabetic rats
and the insulin treated diabetic rats. The striatum, a neuronal nucleus intimately involved in motor
behaviour, is one of the brain regions with the highest acetylcholine content. ACh has complex and
clinically important actions in the striatum that are mediated predominantly by muscarinic
receptors. We observed that insulin treatment brought back the decreased maximal velocity (Vmax)
of acetylcholine esterase in the corpus striatum during diabetes to near control state. In diabetic
rats there was a decrease in maximal number (Bmax) and affinity (Kd) of total muscarinic receptors
whereas muscarinic M1 receptors were increased with decrease in affinity in diabetic rats. We
observed that, in all cases, the binding parameters were reversed to near control by the treatment
of diabetic rats with insulin. Real-time PCR experiment confirmed the increase in muscarinic M1
receptor gene expression and a similar reversal with insulin treatment. These results suggest the
diabetes-induced changes of the cholinergic activity in the corpus striatum and the regulatory role
of insulin on binding parameters and gene expression of total and muscarinic M1 receptors.
Background
The most and well known effects of diabetes mellitus on
CNS is dysfunction of neurotransmitters, which is second-
ary to the metabolic disorders such as hyperglycemia and
acidosis. It has been proposed that an unbalanced auto-
nomic nervous system may be a major cause of the meta-
bolic syndrome [1] Diabetes mellitus have also been
reported to be accompanied by a number of behavioral
and hormonal abnormalities, including hyperphagia,
reduced motor activity [2,3]. CNS abnormalities includ-
ing neuronal atrophy and axonal degenerations [4,5] are
also associated with diabetes. The altered levels of neuro-
transmitter in specific brain areas in patients with diabetes
mellitus [6] and in animals with experimental diabetes [7-
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12] have been documented and implicated in the CNS
disorders. ACh, a major neurotransmitter from auto-
nomic nervous system, regulates the cholinergic stimula-
tion of insulin secretion, through interactions with
muscarinic receptors. Recently we have reported that mus-
carinic M1 receptor gene expressions were decreased in
the cerebral cortex, brainstem, hypothalamus and pancre-
atic islets of STZ induced diabetic rats and insulin modu-
lates the binding parameters and gene expression [13,14].
Acetylcholine muscarinic receptors, members of the
superfamily of G protein-coupled receptors, are classified
pharmacologically into M1 to M5 subtypes, with M1, M3
and M5 receptors preferentially coupling to Gq/11 pro-
teins and M2 and M4 receptors to Gi/o proteins [9]. All
five muscarinic receptors are expressed by striatal neu-
rones, with M1 and M4 receptors as the predominant sub-
types, conforming together nearly 80% of the receptor
population in the rat as shown by immunodetection
[15,16] The main objective of the present study was to
determine whether uncontrolled hyperglycemia, as a con-
sequence of diabetes, altered the acetylcholine esterase
enzyme activity, total and muscarinic M1 receptor bind-
ing parameters and muscarinic M1 receptor gene expres-
sion and the regulatory role of insulin in the rat corpus
striatum.
Materials and methods
Biochemicals used in the present study were purchased
from Sigma Chemical Co., St. Louis, USA. All other rea-
gents were of analytical grade purchased locally. Quinuc-
lidinyl benzilate, L- [Benzilic-4,4'-3H], ([3H] QNB)(Sp.
Activity 42 Ci/mmol) was purchased from NEN life sci-
ences products Inc., Boston, U.S.A. Tri-reagent kit was pur-
chased from MRC, USA. Real Time PCR Taqman probe
assays on demand were purchased from Applied Biosys-
tems, Foster City, CA, USA.
Male adult Wistar rats of 180–240 g body weight were
used for all experiments. They were housed in separate
cages under 12 hour light and 12 hour dark periods. Rats
have free access to standard food and water ad libitum. All
animal care and procedures were in accordance with the
Institutional and National Institute of Health guidelines.
Diabetes was induced in rats by single intrafemoral injec-
tion of streptozotocin freshly dissolved in 0.1 M citrate
buffer, pH 4.5, under anesthesia [17]. Streptozotocin was
given at a dose of 55 mg/Kg body weight [18,19]. Animals
were divided into the following groups: i) Control ii) dia-
betic iii) insulin-treated diabetic rats. Each group con-
sisted of 6–8 animals. The insulin-treated diabetic group
received subcutaneous injections (1 Unit/kg body weight)
of Lente and Plain insulin (Boots India) daily during the
entire period of the experiment. The last injection was
given 24 hrs before sacrificing the rats. Rats were sacrificed
on 15th day by decapitation. The corpus striatum was dis-
sected out quickly over ice according to the procedure of
Glowinski and Iversen 1966[20], the tissues were stored at
-70°C until assayed.
Estimation of blood glucose
Blood glucose was estimated by the spectrophotometric
method using glucose oxidase-peroxidase reactions.
Blood samples were collected from the tail vein at 0 hours
(Before the start of the experiment), 3rd day, 6th day, 10th
day and 14th day and the glucose levels were estimated.
Blood samples were collected 3 hrs after the administra-
tion of morning dose. The results were expressed in terms
of milligram per deciliter of blood.
Acetylcholine Esterase Assay
Acetylcholine esterase asssay was done using the spectro-
photometric method of Ellman et al, (1961) [21]. The cor-
pus striatum homogenate (10%) was prepared in sodium
phosphate buffer (30 mM, pH-7). One ml of 1% Triton ×
100 was added to the homogenate to release the mem-
brane bound enzyme and centrifuged at 10,000 × g for 30
minutes at 4°C. Different concentrations of acetylthio-
choline iodide were used as substrate. The mercaptan
formed as a result of the hydrolysis of the ester reacts with
an oxidising agent 5,5'-dithiobis (2-Nitrobenzoate)
absorbs at 412 nm.
Total Muscarinic and muscarinic M1 receptor binding 
studies in the corpus striatum
[3H]QNB binding assay in corpus striatum was done
according to the modified procedure of Yamamura and
Snyder (1981) [22]. Corpus striatum was homogenised in
a polytron homogeniser with 20 volumes of cold 50 mM
Tris-HCl buffer, containing 1 mM EDTA, pH.7.4. The
supernatant was then centrifuged at 30,000 × g for 30
minutes and the pellets were resuspended in appropriate
volume of Tris-HCl-EDTA buffer.
Total muscarinic receptor binding parameter assays were
done using different concentrations i.e., 0.1–2.5 nM of
[3H] QNB in the incubation buffer, pH 7.4 in a total incu-
bation volume of 250 l containing appropriate protein
concentrations (200–250 g). Non-specific binding was
determined using 100 M atropine. Competition studies
were carried out with 1 nM [3H]QNB in each tube with
atropine concentrations varying from 10-9 – 10-4 M atro-
pine. Tubes were incubated at 22°C for 60 minutes and
filtered rapidly through GF/C filters (Whatman). The fil-
ters were washed quickly by three successive washing with
5.0 ml of ice cold 50 mM Tris-HCl buffer, pH 7.4. Bound
radioactivity was counted with cocktail-T in a Wallac 1409
liquid scintillation counter. The non-specific binding
determined showed 10% in all our experiments.Journal of Biomedical Science 2009, 16:38 http://www.jbiomedsci.com/content/16/1/38
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Muscarinic M1 receptor binding assays were done using
different concentrations i.e., 0.1–2.5 nM of [3H]QNB in
the incubation buffer, pH 7.4 in a total incubation vol-
ume of 250 l containing appropriate protein concentra-
tions (200–250 g). Non-specific binding was
determined using 100 M pirenzepine. Competition stud-
ies were carried out with 1 nM [3H]QNB in each tube with
pirenzepine concentrations varying from 10-9 – 10-4 M.
Tubes were incubated at 22°C for 60 minutes and filtered
rapidly through GF/C filters (Whatman). The filters were
washed quickly by three successive washing with 5.0 ml of
ice cold 50 mM Tris-HCl buffer, pH 7.4. Bound radioactiv-
ity was counted with cocktail-T in a Wallac 1409 liquid
scintillation counter. The non-specific binding deter-
mined showed 10% in all our experiments.
Protein determination
Protein was measured by the method of Lowry et al,
(1951) [23] using bovine serum albumin as standard. The
intensity of the purple blue colour formed was propor-
tional to the amount of protein, which was read in a spec-
trophotometer at 660 nm
Receptor data analysis
The receptor binding parameters were determined using
Scatchard analysis [24]. The specific binding was deter-
mined by subtracting non-specific binding from the total.
The binding parameters, maximal binding (Bmax) and
equilibrium dissociation constant (Kd), were derived by
linear regression analysis by plotting the specific binding
of the radioligand on X-axis and bound/free on Y-axis
using Sigma plot software (version 2.0, Jandel GmbH,
Erkrath, Germany). The maximal binding is a measure of
the total number of receptors present in the tissue and the
equilibrium dissociation constant is the measure of the
affinity of the receptors for the radioligand. The Kd is
inversely related to receptor affinity.
Displacement curve analysis
The displacement data were analysed by nonlinear regres-
sion using GraphPad PRISM™ software, GraphPad Inc.,
San Diego, USA. The concentration of the competing drug
that competes for half the specific binding was defined as
EC50 which is same as IC50. The affinity of the receptor for
the competing drug is designated as Ki and is defined as
the concentration of the competing ligand that will bind
to half the binding sites at equilibrium in the absence of
radioligand or other competitors. The Hill slope was used
to indicate a one or two-sited model of curve-fitting.
Analysis of gene expression by Real-Time PCR
RNA was isolated from the corpus striatum of experimen-
tal rats using the Tri reagent (MRC, USA). Total cDNA syn-
thesis was performed using ABI PRISM cDNA arhive kit in
0.2 ml microfuge tubes. The reaction mixture of 20 l con-
tained 0.2 g total RNA, 10 × RT buffer, 25 × dNTP mix-
ture, 10 × random primers, MultiScribe RT (50 U/l) and
RNase free water. The cDNA synthesis reactions were car-
ried out at 25°C for 10 minutes and 37°C for 2 hours
using an Eppendorf Personal Cycler. Real-time PCR assays
were performed in 96-well plates in ABI 7300 real-time
PCR instrument (Applied Biosystems). The primers and
probes were purchased from Applied Biosystems, Foster
City, California, USA. The TaqMan reaction mixture of 20
l contained 25 ng of total RNA-derived cDNAs, 200 nM
each of the forward primer, reverse primer, and TaqMan
probe for Muscarinic M1 receptor gene and endogenous
control (-actin) and 12.5 l of Taqman 2× Universal PCR
Master Mix (Applied Biosystems) and the volume was
made up with RNAse free water. The following thermal
cycling profile was used (40 cycles): 50°C for 2 min, 95°C
for 10 min, 95°C for 15 sec and 60°C for 1 min.
Fluorescence signals measured during amplification were
considered positive if the fluorescence intensity was 20-
fold greater than the standard deviation of the baseline
fluorescence. The CT method of relative quantification
was used to determine the fold change in expression. This
was done by first normalizing the resulting threshold
cycle (CT) values of the target mRNAs to the CT values of
the internal control -actin in the same samples (CT =
CTTarget – CT-actin). It was further normalize with the con-
trol (CT = CT – CTControl). The fold change in expres-
sion was then obtained as (2-CT) and the graph was
plotted using log 2-CT.
Statistics
Statistical evaluations were done by ANOVA, expressed as
mean ± S.E.M using InStat (Ver.2.04a) computer pro-
gramme.
Results
Blood glucose level of all rats before streptozotocin
administration was within the normal range. Streptozo-
tocin administration led to a significant increase (p <
0.001) in blood glucose level of diabetic rats when com-
pared to control rats. Insulin treatment was able to signif-
icantly reduce (p < 0.001) the increased blood glucose
level to near the control value when compared to diabetic
group (Table 1)
Acetylcholine esterase activity in the Corpus striatum of 
experimental rats
Acetylcholine esterase kinetics studies showed that Vmax
was significantly decreased (p < 0.001) in the corpus stria-
tum of diabetic group with no significant change in Km.
Insulin treatment significantly reversed the Vmax  (p <
0.001) to near control value when compared to diabetic
group (Table 2).Journal of Biomedical Science 2009, 16:38 http://www.jbiomedsci.com/content/16/1/38
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Total Muscarinic receptor analysis
Scatchard analysis of [3H] QNB binding against atropine in the 
corpus striatum of Control, Diabetic and Diabetic+Insulin treated 
diabetic rats
The Scatchard analysis showed that the Bmax and Kd of the
[3H]QNB receptor binding decreased significantly (p <
0.001) in the corpus striatum of diabetic rats when com-
pared to control group. In insulin treated diabetic group
Bmax and Kd were significantly (p < 0.001) reversed back to
near control value when compared to diabetic group. (Fig
1 & Table 3)
Displacement analysis of [3H]QNB using Atropine
In the displacement analysis, the competitive curve fitted
to a one-sited model in all groups with Hill slope values
were near to unity. The log (EC50) did not alter in all the
experimental groups. The Ki decreased in diabetic condi-
tion (Fig 2 & Table 4).
Muscarinic M1 receptor analysis
Scatchard analysis of [3H]QNB binding against pirenzepine in the 
corpus striatum of Control, Diabetic, and Diabetic+Insulin treated 
diabetic rats
The Scatchard analysis showed that the Bmax of muscarinic
M1 receptors of corpus striatum was increased signifi-
cantly (p < 0.001) in diabetic condition when compared
to control group while the Kd was decreased significantly
when compared to control group (p < 0.001). In insulin
treated diabetic rats Bmax was significantly (p < 0.001)
reversed back to near control value when compared to
diabetic group but Kd was not reversed back to near con-
trol value when compared to diabetic group (Fig 3 & Table
5).
Displacement analysis of [3H]QNB using pirenzepine
In the displacement analysis, the competitive curve fitted
to a one-site model in all the experimental conditions.
Hill slopes were near unity confirming the one-site model.
There were no changes in the log (EC50) values. The Ki
value was decreased in diabetic condition (Fig 4 & Table
6).
Real Time-PCR analysis
Real Time-PCR analysis showed that the muscarinic M1
receptor gene expression was increased significantly (p <
0.01) in diabetic condition and it reversed to near control
value in insulin treated diabetic rats (Fig 5 & Table 7).
Discussion
The brain neurotransmitters receptor activity and hormo-
nal pathways control many physiological functions in the
body. The present study analyzed the changes of acetyl-
choline esterase enzyme activity, total muscarinic and
muscarinic M1 receptors in the corpus striatum of STZ
diabetic and insulin-treated diabetic rats. CNS mAChRs
regulate a large number of important central functions
including cognitive, behavioural, sensory, motor and
autonomic processes [25-27]. A key feature of type 2 dia-
betes is that pancreatic -cells fail to release sufficient
amounts of insulin despite elevated blood glucose levels
[28]. Glucose-stimulated insulin secretion (GSIS) is regu-
lated by numerous hormones and neurotransmitters most
of which act on specific G-protein-coupled receptors
(GPCRs) expressed by pancreatic -cells [29,30]. Many
studies have shown that ACh, following its release from
Table 1: Blood glucose (mg/dl) level in Experimental rats
Animal status 0 day (Before STZ injection) 3rd day (Initial) 6th day 10th day 14th day (Final)
Control 86.2 ± 1.4 93.5 ± 1.6 89.4 ± 0.8 101.2 ± 2.2 97.7 ± 1.21
Diabetic 79.4 ± 1.5 253.1 ± 0.5 303.1 ± 0.8 309.7 ± 0.6 311.9 ± 1.4***
D + I 85.2 ± 0.8 256.8 ± 0.5 303.6 ± 0.7 190.9 ± 1.5 137.0 ± 1.3
Values are mean ± S.E.M of 4–6 rats in each group. Each group consist of 6–8 rats
*** P < 0.001 when compared to control,  P < 0.001 when compared to diabetic group,  p < 0.001 when compared with initial reading
Table 2: Acetylcholine esterase activity in the corpus striatum of Control, Diabetic and D+I group rats
Animal status Vmax
(moles/min/mg protein)
Km (M)
Control 2420.0 ± 11.5 51.0 ± 0.5
Diabetic 1631.3 ± 16.1*** 51.3 ± 0.8
Diabetic + Insulin treated (D+I) 2647.0 ± 26.5 51.0 ± 0.5
Values are mean ± S.E.M of 4–6 separate experiments. Each group consist of 6–8 rats
*** P < 0.001 when compared to control,  P < 0.001 when compared to diabetic groupJournal of Biomedical Science 2009, 16:38 http://www.jbiomedsci.com/content/16/1/38
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Representative graph showing Scatchard analysis of [3H]QNB binding against atropine in the corpus striatum of Control, Dia- betic and Diabetic+Insulin treated group rats Figure 1
Representative graph showing Scatchard analysis of [3H]QNB binding against atropine in the corpus striatum 
of Control, Diabetic and Diabetic+Insulin treated group rats. Control (black circle), Diabetic (open circle), Insulin 
treated diabetic rats (black triangle). Total muscarinic receptor binding parameter assays were done using different concentra-
tions i.e., 0.1–2.5 nM of [3H]QNB in the incubation buffer, pH 7.4 in a total incubation volume of 250 l containing appropriate 
protein concentrations (200–250 g). Non-specific binding was determined using 100 M atropine. Tubes were incubated at 
22°C for 60 minutes and filtered rapidly through GF/C filters (Whatman). The filters were washed quickly by three successive 
washing with 5.0 ml of ice cold 50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity was counted with cocktail-T in a Wallac 
1409 liquid scintillation counter. The non-specific binding determined showed 10% in all our experiments.
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Table 3: Scatchard analysis of [3H] QNB binding against atropine in the corpus striatum of Control, Diabetic, and Diabetic+Insulin 
treated group rats
Animal status Bmax
(fmoles/mg protein)
Kd (nM)
Control 214.00 ± 3.05 0.19 ± 0.01
Diabetic 150.00 ± 5.77*** 0.27 ± 0.05***
Diabetic + Insulin treated 184.00 ± 3.05 0.17 ± 0.05
Values are mean ± S.E.M of 4–6 separate experiments. Each group consist of 6–8 rats
*** P < 0.001 when compared to control,  P < 0.001 when compared to diabetic groupJournal of Biomedical Science 2009, 16:38 http://www.jbiomedsci.com/content/16/1/38
Page 6 of 11
(page number not for citation purposes)
intra-pancreatic parasympathetic nerve endings, can stim-
ulate  -cell mAChRs, leading to enhanced GSIS in a
strictly glucose-dependent fashion [29,30]. mAChRs are
members of the superfamily of GPCRs. Molecular-cloning
studies have revealed the existence of five molecularly dis-
tinct mammalian mAChR subtypes, M1-M5 [31,9]. Earlier
studies from our laboratory have established the central
neurotransmitter receptor subtypes functional regulation
during diabetes, pancreatic regeneration and cell prolifer-
ation [32-37]. M1 mAChRs are abundantly expressed in all
major regions of the forebrain, including striatum, hip-
pocampus, and cerebral cortex [38-40,15]. It is therefore
likely that M1 mAChRs play a role in the many central
actions of ACh that involve the activity of forebrain
mAChRs. Pharmacological evidence suggests that M1
receptors are involved in mediating higher cognitive proc-
esses, such as learning and memory [41,42,28]. The stria-
tum, a neuronal nucleus intimately involved in motor
behaviour, is one of the brain regions with the highest ace-
tylcholine content [43]. The mRNA for M1 is present in
more than 80% of striatal neurons [44] including cholin-
ergic neurons, substance P neurons, enkephalin neurons,
and somatostatin neurons [45]. Recent studies from our
laboratory have showed the significance of muscarinic
and muscarinic M1 receptors in the cerebral cortex,
hypothalamus, brainstem, and pancreatic islets of STZ
induced diabetic rats and its functional regulation in insu-
lin secretion. [13,14]. ACh, through vagal muscarinic and
non-vagal muscarnic pathways [46] increases insulin
secretion [47]. They function through muscarinic recep-
tors present on pancreatic islet cells. Receptor localization
studies suggest that multiple muscarinic receptors (M1,
Representative graph showing displacement analysis of [3H]QNB binding against atropine in the hypothalamus of Control, Dia- betic and Diabetic+Insulin treated group rats Figure 2
Representative graph showing displacement analysis of [3H]QNB binding against atropine in the hypothala-
mus of Control, Diabetic and Diabetic+Insulin treated group rats. Control (black circle), Diabetic (upward pointing 
black triangle), Insulin treated diabetic rats (downward pointing black triangle). Competition studies were carried out with 1 
nM [3H]QNB in each tube with atropine concentrations varying from 10-9, 10-4 M. Data were fitted with iterative nonlinear 
regression software (Prism, GraphPad, San Diego, CA). Ki The affinity of the receptor for the competing drug. EC50 is the con-
centration of the competitor that competes for half the specific binding.
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Table 4: Binding parameters of [3H] QNB against atropine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated 
group rats
Experimental Group Best-fit model Log (EC50) Ki Hill slope
Control One-site -7.076 2.10 × 10-8 0.9832
Diabetic One-site -6.818 3.80 × 10-8 0.9883
Insulin treated diabetic One-site -6.913 3.05 × 10-8 0.9889
Values are mean of 4–6 separate experiments. Each group consist of 6–8 ratsJournal of Biomedical Science 2009, 16:38 http://www.jbiomedsci.com/content/16/1/38
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Representative graph showing Scatchard analysis of [3H]QNB binding against pirenzepine in the corpus striatum of Control,  Diabetic and Diabetic+Insulin treated group rats Figure 3
Representative graph showing Scatchard analysis of [3H]QNB binding against pirenzepine in the corpus stria-
tum of Control, Diabetic and Diabetic+Insulin treated group rats. Control (black circle), Diabetic (open circle), Insu-
lin treated diabetic rats (black triangle). Muscarinic M1 receptor binding parameter assays were done using different 
concentrations i.e., 0.1–2.5 nM of [3H]QNB in the incubation buffer, pH 7.4 in a total incubation volume of 250 l containing 
appropriate protein concentrations (200–250 g). Non-specific binding was determined using 100 M pirenzepine. Tubes were 
incubated at 22°C for 60 minutes and filtered rapidly through GF/C filters (Whatman). The filters were washed quickly by 
three successive washing with 5.0 ml of ice cold 50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity was counted with cocktail-
T in a Wallac 1409 liquid scintillation counter. The non-specific binding determined showed 10% in all our experiments.
Table 5: Scatchard analysis of [3H] QNB binding against pirenzepine in the corpus striatum of Control, Diabetic and Diabetic+Insulin 
treated group rats
Animal status Bmax (fmoles/mg protein) Kd (nM)
Control 1460.00 ± 30.55 1.34 ± 0.02
Diabetic 2060.00 ± 30.55*** 0.45 ± 0.02***
Diabetic + Insulin treated 1550.00 ± 28.86 0.56 ± 0.01
Values are mean ± S.E.M of 4–6 separate experiments. Each group consist of 6–8 rats
*** P < 0.001 when compared to control,  P < 0.001 when compared to diabetic groupJournal of Biomedical Science 2009, 16:38 http://www.jbiomedsci.com/content/16/1/38
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M3, M4, and M5) are expressed in pancreatic islets/-cells
[48]. From our previous studies it was observed that mus-
carinic M1 receptors were down-regulated during STZ dia-
betes [13]. The enzyme AChE indirectly plays an
important role in transmission of nerve impulse. It hydro-
lyses the ACh released at the cholinergic synapse and thus
terminates the action of this neurotransmitter. In addition
to their role in cholinergic transmission, cholinesterases
may also play a role during morphogenesis and neurode-
generative diseases [49,50]. We observed a significant
decrease in Vmax of acetylcholine esterase in the striatum
of diabetic rats which was reversed to near control level by
insulin treatment. Akmayev et al (1978) [51] showed that
there is a difference in distribution of enzyme in the neu-
rons of the central vagal nuclei in normal and adult male
rats. It is suggested that the changes in the plasma glucose
or insulin may be that stimulus that influence the activity
of cholinergic neurons. Insulin treatment reversed the
altered maximum velocity toward the control level. Cor-
pus striatum is best known for its role in the planning and
modulation movement pathways but also involved in a
variety of cognitive process involving executive function.
In corpus striatum total muscarinic receptor numbers and
affinity were decreased during diabetes, whereas mus-
Representative graph showing displacement analysis of [3H]QNB binding against pirenzepine in the corpus striatum of Control,  Diabetic and Diabetic+Insulin treated group rats Figure 4
Representative graph showing displacement analysis of [3H]QNB binding against pirenzepine in the corpus 
striatum of Control, Diabetic and Diabetic+Insulin treated group rats. Control (black circle), Diabetic (upward 
pointing black triangle), Insulin treated diabetic rats (downward pointing black triangle). Competition studies were carried out 
with 1 nM [3H]QNB in each tube with pirenzepine concentrations varying from 10-9 to 10-4 M. Data were fitted with iterative 
nonlinear regression software (Prism, GraphPad, San Diego, CA). Ki – The affinity of the receptor for the competing drug. EC50 
is the concentration of the competitor that competes for half the specific binding.
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Table 6: Binding parameters of [3H]QNB against pirenzepine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated 
group rats
Experimental Group Best-fit model Log (EC50) Ki Hill slope
Control One-site -7.107 2.23 × 10-8 0.7224
Diabetic One-site -6.459 9.92 × 10-8 0.7444
Insulin treated diabetic One-site -7.322 4.76 × 10-8 0.6826
Values are mean of 4–6 separate experiments. Each group consist of 6–8 ratsJournal of Biomedical Science 2009, 16:38 http://www.jbiomedsci.com/content/16/1/38
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carinic M1 receptors number was increased in STZ dia-
betic rats with decrease in affinity. The changes in the
receptor number and affinity observed are due to the alter-
ations of receptor protein and synthesis. Real-time PCR
analysis showed an up-regulation of the muscarinic M1
receptor mRNA level in the striatum of diabetic rats,
whereas it reversed to near control when treated with
insulin. This is in accordance with our receptor binding
studies. ACh has complex and clinically important actions
in the striaturn that are mediated predominantly by mus-
carinic receptors. Based on physiological and pharmaco-
logical studies, several specific actions of ACh in the
striatum have been suggested. ACh regulates its own
release from cholinergic interneurons through presynap-
tic autoreceptors. Noncholinergic striatal neurons are
directly affected by ACh through postsynaptic receptors
and presynaptic heteroceptors and the release of excita-
tory amino acids and dopamine by extrinsic striatal affer-
Representative graph showing Real-Time amplification of muscarinic M1 mRNA from the corpus striatum of control, diabetic  and insulin treated diabetic rats Figure 5
Representative graph showing Real-Time amplification of muscarinic M1 mRNA from the corpus striatum of 
control, diabetic and insulin treated diabetic rats. Control, Diabetic, Insulin treated diabetic rats. The CT method of 
relative quantification was used to determine the fold change in expression. This was done by first normalizing the resulting 
threshold cycle (CT) values of the target mRNAs to the CT values of the internal control -actin in the same samples (CT = 
CTTarget – CT -actin). It was further normalize with the control (CT = CT – CTControl). The fold change in expression was 
then obtained (2-CT). The graph was plotted using log 2-CT. Values are mean ± S.D of 4–6 separate experiments. Relative 
Quantification values and standard deviations are shown in the table. The relative ratios of mRNA levels were calculated using 
the CT method normalized with -actin CT value as the internal control and Control CT value as the calibrator.
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Table 7: Real Time amplification of Muscarinic M1 receptor 
mRNA from the Corpus striatum of Control, Diabetic, and 
Diabetic+Insulin treated group rats
Experimental group RQ Value
Control 0
Diabetic 3.14 ± 0.25**
Diabetic + Insulin treated 0.86 ± -0.66
Values are mean ± S.D of 4–6 separate experiments. Each group 
consist of 6–8 rats Relative Quantification values and standard 
deviations are shown in the table. The relative ratios of mRNA levels 
were calculated using the CT method normalized with -actin CT 
value as the internal control and Control CT value as the calibrator.
** p < 0.01 when compared with control
p < 0.01 when compared with diabetic groupJournal of Biomedical Science 2009, 16:38 http://www.jbiomedsci.com/content/16/1/38
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ents may be under presynaptic control of ACh through
presynaptic heteroceptors [52-54]. In diabetic corpus
striatum total muscarinic receptors activities were
decreased. The insulin treatment reversed these altered
parameters to near control level. Muscarinic receptor sub-
types other than M1 may also be affected by the diabetic
condition. Further studies have to be carried out to eluci-
date the role of other subtypes. The present study suggests
that drugs that can selectively activate muscarinic recep-
tors may be of significant therapeutic benefit in the diabe-
tes management. Thus our results revealed the
significance of central muscarinic receptor changes during
diabetes and the regulatory role of insulin on muscarinic
receptors.
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